Outcomes following dialysis and transplantation in amyloidosis: ANZDATA analysis.
12 affiliations
- 1Department of Renal Medicine and Transplant, Westmead Hospital, Sydney, NSW, Australia.
- 2The University of Sydney, Sydney, NSW, Australia.
- 3Children's Hospital at Westmead Centre for Kidney Research, Westmead, NSW, Australia.
- 4Centre for Transplant and Renal Research, Westmead Institute for Medical Research, 176 Hawkesbury Road, Westmead, NSW, 2145, Australia.
- 5Department of Renal Medicine, Blacktown & Mount Druitt Hospital, Sydney, NSW, Australia.
- 6Western Sydney University, Sydney, NSW, Australia.
- 7Department of Renal Medicine, Nepean Hospital, Sydney, NSW, Australia.
- 8The George Institute for Global Health, Sydney, NSW, Australia.
- 9Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
- 10Department of Renal Medicine and Transplant, Westmead Hospital, Sydney, NSW, Australia. [email protected].
- 11The University of Sydney, Sydney, NSW, Australia. [email protected].
- 12Centre for Transplant and Renal Research, Westmead Institute for Medical Research, 176 Hawkesbury Road, Westmead, NSW, 2145, Australia. [email protected].
Abstract
Background
The kidneys are frequently affected by systemic amyloidosis. Despite this, contemporary survival outcomes for patients reaching kidney failure due to amyloidosis remain poorly defined relative to other causes of kidney failure. This study aims to characterise patient survival with renal amyloidosis requiring kidney replacement therapy (KRT) and directly compare these outcomes with diabetic nephropathy, glomerular disease, and polycystic kidney disease (PKD).Methods
This was a retrospective cohort study using the Australia and New Zealand Dialysis and Transplant Registry for patients who initiated KRT between 1990 and 2022. A propensity-matched analysis was performed at 1:4 ratio for amyloidosis versus PKD, glomerular disease and diabetes. Patients were matched for age, sex, treatment era, comorbidities and dialysis vintage. Kaplan-Meier survival curves and Cox proportional hazards were used to compare patient survival on dialysis and post-transplant.Results
84,148 incident dialysis patients were included, of which 654 (0.8%) had kidney failure attributed to amyloidosis. Using amyloidosis as the reference group, matched comparator cohorts had lower mortality hazards: diabetic nephropathy (HR 0.68, 95% CI 0.62-0.74), glomerular disease (HR 0.38, 95% CI 0.34-0.42), and PKD (HR 0.28, 95% CI 0.26-0.32). 23,463 incident transplant recipients were included, of which 48 (0.2%) had kidney failure secondary to amyloidosis. Using amyloidosis as the reference group, post-transplant mortality hazards were similar for T2DM (HR 1.00, 95% CI 0.75-1.35), but lower for T1DM (HR 0.72, 95% CI 0.52-0.98), glomerular disease (HR 0.40, 95% CI 0.28-0.57), and PKD (HR 0.38, 95% CI 0.29-0.56). Amyloidosis subtype data were unavailable, limiting assessment of disease-specific outcomes.Conclusions
Kidney failure due to amyloidosis was associated with markedly worse survival on dialysis and less favourable post-transplant patient survival compared with several comparator kidney diseases. However, death-censored graft survival appeared broadly comparable, suggesting that excess post-transplant risk is largely driven by patient mortality rather than intrinsic graft failure.
Related
- Systemic Amyloidosis After Liver Transplantation From a Donor With Hereditary Transthyretin Amyloidosis
- Systemic AA Amyloidosis Following Immune Checkpoint Inhibitor Therapy for Lung Carcinosarcoma: An Autopsy Case and Review of the Literature
- Effects of faecal microbiota transplantation on glycaemic outcomes in adults with metabolic disorders: a systematic review and meta-analysis of randomised controlled trials
- A Progressive 99mTc-MDP Uptake in Transthyretin Cardiac Amyloidosis
- The Progressive Cardiac Uptake of 99mTc-MDP as a Clue to Transthyretin Amyloidosis
BibTeX
@article{jayanti2026outcomes,
title = {{Outcomes following dialysis and transplantation in amyloidosis: ANZDATA analysis.}},
author = {Sumedh Jayanti and Dharshana Sabanayagam and Joshua L Lee and Katrina Chau and Bhadran Bose and Brian J Nankivell and Fiona Kwok and Jennifer S Y Li},
journal = {BMC nephrology},
year = {2026},
month = aug,
doi = {10.1186/s12882-026-05230-3},
url = {https://europepmc.org/article/MED/42968043},
note = {CC BY},
}
RIS
TY - JOUR
TI - Outcomes following dialysis and transplantation in amyloidosis: ANZDATA analysis.
AU - Sumedh Jayanti
AU - Dharshana Sabanayagam
AU - Joshua L Lee
AU - Katrina Chau
AU - Bhadran Bose
AU - Brian J Nankivell
AU - Fiona Kwok
AU - Jennifer S Y Li
PY - 2026
DA - 2026/08/03
JO - BMC nephrology
DO - 10.1186/s12882-026-05230-3
UR - https://europepmc.org/article/MED/42968043
AB - Background The kidneys are frequently affected by systemic amyloidosis. Despite this, contemporary survival outcomes for patients reaching kidney failure due to amyloidosis remain poorly defined relative to other causes of kidney failure. This study aims to characterise patient survival with renal amyloidosis requiring kidney replacement therapy (KRT) and directly compare these outcomes with diabetic nephropathy, glomerular disease, and polycystic kidney disease (PKD).Methods This was a retrospective cohort study using the Australia and New Zealand Dialysis and Transplant Registry for patients who initiated KRT between 1990 and 2022. A propensity-matched analysis was performed at 1:4 ratio for amyloidosis versus PKD, glomerular disease and diabetes. Patients were matched for age, sex, treatment era, comorbidities and dialysis vintage. Kaplan-Meier survival curves and Cox proportional hazards were used to compare patient survival on dialysis and post-transplant.Results 84,148 incident dialysis patients were included, of which 654 (0.8%) had kidney failure attributed to amyloidosis. Using amyloidosis as the reference group, matched comparator cohorts had lower mortality hazards: diabetic nephropathy (HR 0.68, 95% CI 0.62-0.74), glomerular disease (HR 0.38, 95% CI 0.34-0.42), and PKD (HR 0.28, 95% CI 0.26-0.32). 23,463 incident transplant recipients were included, of which 48 (0.2%) had kidney failure secondary to amyloidosis. Using amyloidosis as the reference group, post-transplant mortality hazards were similar for T2DM (HR 1.00, 95% CI 0.75-1.35), but lower for T1DM (HR 0.72, 95% CI 0.52-0.98), glomerular disease (HR 0.40, 95% CI 0.28-0.57), and PKD (HR 0.38, 95% CI 0.29-0.56). Amyloidosis subtype data were unavailable, limiting assessment of disease-specific outcomes.Conclusions Kidney failure due to amyloidosis was associated with markedly worse survival on dialysis and less favourable post-transplant patient survival compared with several comparator kidney diseases. However, death-censored graft survival appeared broadly comparable, suggesting that excess post-transplant risk is largely driven by patient mortality rather than intrinsic graft failure.
SN - 1471-2369
ER -